BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 180 filers reported holding BRIDGEBIO PHARMA INC in Q4 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,702 | +58.8% | 100,000 | 0.0% | 0.01% | +50.0% |
| Q2 2023 | $1,702 | -0.3% | 100,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,707 | +357.6% | 100,000 | +100.0% | 0.00% | +300.0% |
| Q4 2022 | $373 | -99.9% | 50,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $500,000 | +45.3% | 50,000 | +25.6% | 0.00% | 0.0% |
| Q2 2022 | $344,000 | -16.7% | 39,800 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $413,000 | -20.1% | 39,800 | +9.9% | 0.00% | 0.0% |
| Q4 2021 | $517,000 | -68.6% | 36,200 | +2.8% | 0.00% | -80.0% |
| Q3 2021 | $1,648,000 | -47.3% | 35,200 | -33.8% | 0.01% | -44.4% |
| Q2 2021 | $3,130,000 | +1.3% | 53,200 | 0.0% | 0.01% | -10.0% |
| Q1 2021 | $3,089,000 | +21.4% | 53,200 | +39.3% | 0.01% | 0.0% |
| Q4 2020 | $2,545,000 | +75.5% | 38,200 | -4.7% | 0.01% | +66.7% |
| Q3 2020 | $1,450,000 | – | 40,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |